resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
RTB101 were inhibiting mTORC1, to minimize side effects of whole TOR inhibition, and targeting respiratory illness.
https://ir.restorbio.com/news-releases/ ... linically/
Longevity ⇒ mTOR inhibition Phase 3 clinical trial fails.
mTOR inhibition Phase 3 clinical trial fails.
Ph.D. student at Harvard Medical School, doing research on aging
Re: mTOR inhibition Phase 3 clinical trial fails.
This is disappointing but I hope some of the other research regarding mTor inhibition will provide satisfying results especially in the Parkinson diagnosis catagory.
Thank you for sharing this research
Thank you for sharing this research
-
- Posts: 541
- Joined: Tue Aug 20, 2019 5:31 pm
Re: mTOR inhibition Phase 3 clinical trial fails.
Failure is disappointing, but the scientific method is paving the way for accurate, successful treatments.
This is patently obvious to many people here, but some times anecdotal evidence is not evidence at all - it needs the trials.
This is patently obvious to many people here, but some times anecdotal evidence is not evidence at all - it needs the trials.